Back to top
more

Cytek Biosciences (CTKB)

(Delayed Data from NSDQ)

$5.30 USD

5.30
784,663

-0.05 (-0.93%)

Updated Aug 14, 2024 04:00 PM ET

After-Market: $5.30 0.00 (0.00%) 7:02 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for CTKB

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for Cytek Biosciences, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 263 344 365 166 -99,999
Receivables 56 49 30 17 NA
Notes Receivable 0 0 0 0 NA
Inventories 61 48 32 23 NA
Other Current Assets 13 13 5 3 NA
Total Current Assets 392 454 432 209 NA
Net Property & Equipment 18 14 6 2 NA
Investments & Advances 0 0 0 0 NA
Other Non-Current Assets 0 0 0 0 NA
Deferred Charges 30 20 9 7 NA
Intangibles 39 14 15 1 NA
Deposits & Other Assets 3 3 2 1 NA
Total Assets 494 519 463 220 NA
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 NA
Accounts Payable 3 5 3 3 NA
Current Portion Long-Term Debt 0 0 0 0 NA
Current Portion Capital Leases 0 0 0 0 NA
Accrued Expenses 20 21 15 9 NA
Income Taxes Payable 0 0 0 0 NA
Other Current Liabilities 33 23 15 15 NA
Total Current Liabilities 56 49 33 27 NA
Mortgages 0 0 0 0 NA
Deferred Taxes/Income 15 13 10 3 NA
Convertible Debt 0 0 0 0 NA
Long-Term Debt 2 2 0 0 NA
Non-Current Capital Leases 0 0 0 0 NA
Other Non-Current Liabilities 19 17 15 12 NA
Minority Interest (Liabilities) 0 0 0 0 NA
Total Liabilities 101 94 58 42 NA
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 194 NA
Common Stock (Par) 0 0 0 0 NA
Capital Surplus 423 443 424 6 NA
Retained Earnings -29 -17 -20 -23 NA
Other Equity -1 0 1 0 NA
Treasury Stock 0 0 0 0 NA
Total Shareholder's Equity 393 426 405 178 NA
Total Liabilities & Shareholder's Equity 494 519 463 220 NA
Total Common Equity 393 426 405 -16 0
Shares Outstanding 135.50 134.80 133.70 NA NA
Book Value Per Share 2.90 3.16 3.03 0.00 0.00

Fiscal Year End for Cytek Biosciences, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents 277 270 263 288 299
Receivables 45 50 56 55 50
Notes Receivable 0 0 0 0 0
Inventories 50 55 61 67 66
Other Current Assets 12 13 13 12 11
Total Current Assets 384 389 392 422 425
Net Property & Equipment 18 18 18 17 16
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 30 33 30 24 26
Intangibles 38 38 39 41 43
Deposits & Other Assets 5 4 3 3 3
Total Assets 484 492 494 519 525
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable 0 0 0 0 0
Accounts Payable 3 4 3 5 3
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 15 18 20 21 20
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 34 34 33 33 31
Total Current Liabilities 52 56 56 59 54
Mortgages 0 0 0 0 0
Deferred Taxes/Income 14 15 15 15 16
Convertible Debt 0 0 0 0 0
Long-Term Debt 1 1 2 2 2
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 19 19 18 19
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 95 99 101 104 101
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock 0 0 0 0 0
Common Stock (Par) 0 0 0 0 0
Capital Surplus 435 429 423 452 454
Retained Earnings -46 -35 -29 -35 -28
Other Equity 0 -2 -1 -2 -2
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 389 393 393 416 424
Total Liabilities & Shareholder's Equity 484 492 494 519 525
Total Common Equity 389 393 393 416 424
Shares Outstanding 131.20 131.20 135.50 136.30 135.60
Book Value Per Share 2.97 2.99 2.90 3.05 3.13